● Recruiting

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Condition: Solid Tumor Cancer · Medulloblastoma · High Risk Neuroblastoma · Sponsor: Fundación de investigación HM

PhasePhase 1/Phase 2

Planned participants25

Who can joinAll sexes, 3 Years to no upper limit

Healthy volunteersNo

About this study

Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

This description comes directly from the study's public registry record.

Talk to the study team

Marta Osuna Marco MD, Medical Degree · +34 917 08 99 35 · marta.osuna@startmadrid.com

START Pediatrics · pediatrics@startresearch.com

Always discuss trial participation with your own doctor first.

Locations (1)

HM Monteprincipe

Boadilla del Monte, Madrid, Spain

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06607692